The US Federal Drug Administration (FDA) has issued a safety advisory statement for tofacitinib (Xeljanz) warning prescribers not to exceed the recommended dose in patients with rheumatoid arthritis. The alert follows a postmarketing safety clinical trial of tofactinib in combination with methotrexate that found an increased risk of pulmonary embolism and death with a 10mg ...
Don’t exceed recommended dose with tofacitinib in RA, FDA advises
By Michael Woodhead
26 Feb 2019